factor glp 1 balance meals GLP-1 Meal Plan Power Up on Protein: Mini
Description
The drugs are approved in Canada for diabetic treatment
Scientific References: Marathe CS, Rayner CK, Jones KL, Horowitz M
This is a real, clinically actionable signal that has been reported in trials independently of this analysis
Tirzepatide activates both, offering enhanced anti-inflammatory effects
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial
High gastrointestinal discontinuation rates exceeding 50% across all doses, combined with liver safety signals in early studies, ultimately led Pfizer to discontinue danugliprons development in April 2025
